VLKIM
BMY icon

Van Lanschot Kempen Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Van Lanschot Kempen Investment Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,014
Closed -$54.7K – 242
2025
Q4 		$54.7K Sell
1,014
-34,486
-97% -$1.66M ﹤0.01% 246
2025
Q3 		$1.6M Sell
35,500
-85,696
-71% -$4M 0.01% 225
2025
Q2 		$5.61M Buy
121,196
+33,103
+38% +$1.62M 0.05% 203
2025
Q1 		$5.37M Buy
88,093
+9,581
+12% +$558K 0.06% 184
2024
Q4 		$4.44M Buy
78,512
+77,923
+13,230% +$4.35M 0.04% 185
2024
Q3 		$30.5K Sell
589
-3,843
-87% -$180K ﹤0.01% 212
2024
Q2 		$184K Hold
4,432
– – ﹤0.01% 204
2024
Q1 		$240K Sell
4,432
-35
-0.8% -$1.78K ﹤0.01% 201
2023
Q4 		$229K Buy
4,467
+3,808
+578% +$200K ﹤0.01% 203
2023
Q3 		$38.2K Hold
659
– – ﹤0.01% 197
2023
Q2 		$42.1K Sell
659
-48,239
-99% -$3.23M ﹤0.01% 198
2023
Q1 		$3.39M Buy
48,898
+2,729
+6% +$192K 0.06% 145
2022
Q4 		$3.32M Buy
46,169
+332
+0.7% +$25K 0.1% 133
2022
Q3 		$3.26M Buy
45,837
+2,165
+5% +$157K 0.13% 114
2022
Q2 		$3.36M Buy
43,672
+1,653
+4% +$126K 0.12% 117
2022
Q1 		$3.07M Buy
42,019
+11,870
+39% +$797K 0.09% 123
2021
Q4 		$1.88M Sell
30,149
-1,641
-5% -$96.3K 0.06% 142
2021
Q3 		$1.88M Buy
31,790
+1,281
+4% +$84.4K 0.07% 142
2021
Q2 		$2.04M Buy
30,509
+1,271
+4% +$82.9K 0.07% 142
2021
Q1 		$1.85M Buy
29,238
+3,971
+16% +$247K 0.08% 127
2020
Q4 		$1.57M Sell
25,267
-3,838
-13% -$236K 0.09% 128
2020
Q3 		$1.75M Buy
29,105
+1,298
+5% +$78.1K 0.13% 110
2020
Q2 		$1.64M Buy
27,807
+12,231
+79% +$732K 0.12% 109
2020
Q1 		$868K Sell
15,576
-296
-2% -$18.1K 0.07% 133
2019
Q4 		$1.02M Buy
15,872
+15,101
+1,959% +$865K 0.06% 131
2019
Q3 		$39K Hold
771
– – ﹤0.01% 173
2019
Q2 		$35K Hold
771
– – ﹤0.01% 178
2019
Q1 		$37K Buy
+771
New +$38.4K ﹤0.01% 180

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Van Lanschot Kempen Investment Management's BMY Position: Q1 2026 in Review

Van Lanschot Kempen Investment Management sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 1,014 shares — an estimated $54.7K sold.

Van Lanschot Kempen Investment Management first reported a position in BMY in Q1 2019 and held it in 28 quarters. The position peaked at $5.61M in Q2 2025. 2,527 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Van Lanschot Kempen Investment Management reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
  • Van Lanschot Kempen Investment Management sold 1,014 Bristol-Myers Squibb shares in Q1 2026, an estimated $54.7K.
  • Van Lanschot Kempen Investment Management first reported a position in Bristol-Myers Squibb in Q1 2019 and held it in 28 quarters.
  • Van Lanschot Kempen Investment Management's Bristol-Myers Squibb position peaked at $5.61M in Q2 2025.
  • 2,527 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Van Lanschot Kempen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.